Acute myeloid leukaemia trials in China

In China 226 Also abroad 763

226 trials · From ClinicalTrials.gov, checked 13 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT
Where
Tianjin
Age
18 years to 65 years
People
30
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06447090
Phase 3Not yet taking people in China
Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR
Where
Shanghai
Age
16 years to 65 years
People
220
Run by
Ruijin Hospital
See details and how to joinNCT06297772
Phase 2Taking people
Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients
Where
Suzhou
Age
18 years to 65 years
People
60
Run by
The First Affiliated Hospital of Soochow University
See details and how to joinNCT06394011
Phase 1/2Not yet taking people in China
A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia
Where
Tianjin
Age
18 years and over
People
180
Run by
Akeso
See details and how to joinNCT06387420
Phase 1/2Taking people
TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
Where
Tianjin
Age
18 years and over
People
30
Run by
Shenzhen TargetRx Co., Ltd.
See details and how to joinNCT06206174
Phase 3Taking people
MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
Where
Huanggang, Jingzhou, Shiyan, Taiyuan, Wuhan, Wuxi, Xianning, Xiaogan, Yichang, Zhengzhou
Age
18 years to 75 years
People
154
Run by
Zhongnan Hospital
See details and how to joinNCT06345365
No phaseTaking people
A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML
Where
Shanghai
Age
18 years to 75 years
People
78
Run by
Ruijin Hospital
See details and how to joinNCT06329999
No phaseTaking people
Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.
Where
Huai'an
Age
18 years to 60 years
People
34
Run by
Huai'an First People's Hospital
See details and how to joinNCT06328179
No phaseTaking people
The Maintenance Treatment of "ITIVA" in AML Patients
Where
Zhengzhou
Age
14 years and over
People
130
Run by
Henan Cancer Hospital
See details and how to joinNCT06256627
No phaseTaking people
Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML
Where
Nanjing
Age
18 years to 60 years
People
54
Run by
The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT06232694
Phase 1/2Taking people
Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)
Where
Xuzhou
Age
18 years to 70 years
People
20
Run by
Xuzhou Medical University
See details and how to joinNCT06125652
No phaseTaking people
A Study of Chidamide With AZA in MRD Positive AML After Transplant
Where
Guangzhou
Age
18 years and over
People
60
Run by
Guangdong Provincial People's Hospital
See details and how to joinNCT06066905
No phaseNot yet taking people in China
A Multicenter Prospective Cohort Study Study of CLAG Regimen in Acute Myeloid Leukemia Patients With First-induction Failure
Where
Guanzhou
Age
14 years to 65 years
People
137
Run by
Nanfang Hospital, Southern Medical University
See details and how to joinNCT05875649
No phaseTaking people
Clinical Study Protocol of Maintenance Therapy With Venetoclax in Elderly Patients With AML in First Complete Remission
Where
Nanjing
Age
60 years to 85 years
People
100
Run by
The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT05909293
Phase 2/3Taking people
Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML
Where
Suzhou
Age
18 years to 60 years
People
60
Run by
The First Affiliated Hospital of Soochow University
See details and how to joinNCT05805098
Phase 2Taking people
A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia
Where
Ch’ang-ch’un, Changzhou, Chengdu, Ha’erbin, Hefei, Jiaxing, Lanzhou, Ningbo, Shanghai, Shenyang, Shijia Zhuang, Ürümqi, Wuhu, Xi'an, Yangzhou, Yixing
Age
18 years and over
People
58
Run by
Shanghai Tong Ren Hospital
See details and how to joinNCT05736965
Phase 2Taking people
Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results
Where
Shanghai
Age
18 years and over
People
58
Run by
Shanghai Tong Ren Hospital
See details and how to joinNCT05736978
Phase 1/2Taking people
Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT
Where
Chengdu
Age
18 years to 65 years
People
77
Run by
Sichuan University
See details and how to joinNCT05682755
Phase 1/2Taking people
Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML
Where
Nanjing
Age
18 years to 80 years
People
50
Run by
The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT05584761
Phase 2Taking people
Olverembatinib for FGFR1-rearranged Neoplasms
Where
Suzhou
People
20
Run by
The First Affiliated Hospital of Soochow University
See details and how to joinNCT05521204
Phase 2/3Taking people
AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission
Where
Suzhou
Age
18 years to 64 years
People
124
Run by
The First Affiliated Hospital of Soochow University
See details and how to joinNCT05404906
Phase 1Taking people
Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia
Where
Wuhan
Age
18 years to 70 years
People
12
Run by
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT05445011
Phase 1/2Taking people
SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Where
Chengdu
Age
18 years to 59 years
People
58
Run by
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
See details and how to joinNCT05445154
Early phase 1Taking people
CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases
Where
Hangzhou
People
108
Run by
Zhejiang University
See details and how to joinNCT04662294
Early phase 1Not yet taking people in China
NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia
Where
Hangzhou
Age
3 years to 70 years
People
36
Run by
Zhejiang University
See details and how to joinNCT04658004